Dr. Dirk Jochmans is a research manager at the University of Leuven (KU Leuven, Neyts lab) since 2010. He has more than 10 years’ experience in pharmaceutical drug discovery in industry (Tibotec, J&J), where he coordinated early discovery programs of novel antivirals against HIV. He is currently involved in different European programs focusing on novel antiviral therapies for neglected and emerging viral infections.
Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol. 2013 Apr;3(2):217-24
Jochmans D, Leyssen P, Neyts J. A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE. J Virol Methods. 2012 Aug;183(2) :176-9
Boyer J, Arnoult E, Médebielle M, Guillemont J, Unge J, Jochmans D. Difluoromethylbenzoxazole pyrimidine thioether derivatives: a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem. 2011 Dec 8;54(23):7974-85
Jochmans D, Anders M, Keuleers I, Smeulders L, Kräusslich HG, Kraus G, Müller B. Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease. Retrovirology. 2010 Oct 15;7:89
Jochmans D, Deval J, Kesteleyn B, Van Marck H, Bettens E, De Baere I, Dehertogh P, Ivens T, Van Ginderen M, Van Schoubroeck B, Ehteshami M, Wigerinck P, Götte M, Hertogs K. Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J Virol. 2006 Dec;80(24):12283-92